N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders

1. A compound of Formula II:

wherein,

X, Y, Z and G are each independently selected from the group consisting of N and C(R 3 );

the subscript q is 0, 1, or 2;

the subscript k is 1, 2 or 3;

R 1 is selected from the group consisting of H, C 1-10 alkyl, C 3-7 cycloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, —X 1 —C(O)R a , —X 1 —C(O)OR a , —X 1 —C(O)NR a R b , —S(O) 2 R a , a 4- to 7-membered heterocyclyl group, aryl and a 5- to 10-membered heteroaryl group, wherein each of said cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group is optionally substituted with from 1 to 4 substituents independently selected from the group consisting of halo, C 1-10 alkyl, C 1-10 haloalkyl, C 1-10 alkyl substituted with a —C(O)OR c or —C(O)NR c R d , C 3-7 cycloalkyl, aryl, heteroaryl, —CN, —NR a C(O)R b , —NR a C(O)NR a R b , —NO 2 , —OR a , —NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —SR a , —S(O)R a , —S(O) 2 R a , —NR a S(O) 2 R b , and —S(O) 2 NR a R b , or optionally R a and R b are combined to form a 4-, 5- or 6-membered unsubstituted ring, and X 1 is selected from the group consisting of a bond, C 1-4 alkylene, C 2-6 alkenylene, C 2-6 ,alkynylene, —C(O)—, and —C(O)(CH 2 ) 1-4 ; wherein R c and R d arc independently H or C 1-10 alkyl;

each R 2 is independently selected from the group consisting of halo, C 1-5 alkyl, C(O)R a , —C(O)OR a , —C(O)NR a R b , —OR a , —NR a R b , —NR a C(O)R b , —S(O)R a R b , —S(O) 2 R a and —S(O) 2 NR a R b , and wherein when the subscript q is 2, two R 2 groups can optionally cyclize to form a ring;

each R 3 is independently selected from the group consisting of H, halo, C 1-4 alkyl, C 1-4 haloalkyl, C 3-7 cycloalkyl, aryl and OR c ;

each R 6 is independently selected from the group consisting of halo, C 1-10 alkyl, C 1-10 haloalkyl, C 3-7 cycloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, CN, NO 2 , ——OR a , —NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —NR a C(O)R b , —NR a C(O)OR b , —NR a C(O)NR a R b , —SR a , —S(O)R a , S(O) 2 R a , —NR a S(O)R b , —NR a S(O) 2 R b , —S(O) 2 NR a R b , a 4- to 7-membered heterocyclyl group, aryl and a 5- to 10-membered heteroaryl group;

and each R a and R b is independently selected from the group consisting of H, C 1-10 alkyl, C 1-10 haloalkyl, C 3-10 cycloalkyl, heterocyclyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl, 5- to 6-membered heteroaryl and arylC 1-4 alkyl; and wherein the aliphatic portions of each of said R a and R b is optionally substituted with from one to three groups selected from the group consisting of halo, —OR n , —OC(O)R n , —OC(O)N(R n ) 2 , —SR n , —S(O)R n , —S(O) 2 R n , —S(O) 2 N(R n ) 2 , —NR n S(O) 2 R n , —C(O)N(R n ) 2 , —C(O)R n , —NR n C(O)R n , —NR n C(O)N(R n ) 2 , —C(O)OR n , —NR n C(O)OR n , —CN, —NO 2 , —N(R n ) 2 and —NR n S(O) 2 N(R n ) 2 , wherein each R n is independently H, C 1-3 haloalkyl or an unsubstituted C 1-6 alkyl;

each R 7 and R 8 is independently selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl;

or a pharmaceutically acceptable salt, stereoisomer, and/or ester thereof.

2. The compound of claim 1 , wherein q is 0 or 1 and, both R 7 and R 8 are H.

3. The compound of claim 1 , wherein the ring having X, Y, and Z is selected from the group consisting of

4. The compound of claim 3 , wherein R 3 is H.

5. The compound of claim 1 , wherein R 1 is selected from the group consisting of —X 1 —C(O)R a , —X 1 —C(O)OR a , optionally substituted aryl and optionally substituted heteroaryl group.

6. The compound of claim 5 , wherein R 1 is —C(O)OR a , pyrimidine optionally substituted with from one to two substituents independently selected from the group consisting of halo, C 3-6 cycloalkyl, and C 1-10 alkyl, or oxadiazole optionally substituted with from one to two substituents independently selected from the group consisting of halo, C 3-6 cycloalkyl, and C 1-10 alkyl.

7. The compound of claim 1 , wherein the subscript k is 1 or 2.

8. The compound of claim 7 , wherein each R 6 is independently selected from the group consisting of halo, —NR a R b , —NR a C(O)R b , —S(O)R a , —S(O) 2 R a , C 1-3 alkyl, C 1-3 haloalkyl substituted heteroaryl and unsubstituted heteroaryl.

9. The compound of claim 8 wherein k is 2, and each R 6 is independently selected from the group consisting of fluoro, chloro, methyl, ethyl, —CF 3 , imidazolyl, triazolyl, tetrazolyl, —S(O)R a , and —S(O) 2 R a .

10. The compound of claim 7 wherein R 1 is a heteroaryl group optionally substituted with from one to two substituents selected from the group consisting of halo, C 1-6 alkyl, and C 1-6 haloalkyl, and each R 6 is independently selected from the group consisting of halo, —NR a R b , —NR a C(O)R b , —S(O)R a , —S(O) 2 R a , C 1-3 alkyl, C 1-3 haloalkyl substituted heteroaryl and unsubstituted heteroaryl.

11. The compound of claim 10 , wherein R 1 is a substituted pyrimidinyl or substituted oxadiazolyl group, and each R 6 is independently selected from the group consisting of fluoro, chloro, methyl, ethyl, —CF 3 , imidazolyl, triazolyl, tetrazolyl, —S(O)R a , and —S(O) 2 R a .

12. The compound of claim 7 , wherein k is 2, R 1 is a pyrimidinyl group optionally substituted with from one to two substituents selected from the group consisting of halo, C 1-6 alkyl, and C 1-6 haloalkyl, and each R 6 is independently selected from the group consisting of fluoro, chloro, methyl, ethyl, —CF 3 , imidazolyl, triazolyl, tetrazolyl, —S(O)R a , and —S(O) 2 R a .

13. A compound or a pharmaceutically acceptable salt, tautomer, stereoisomer, or ester thereof, wherein the compound is selected from group consisting of

4-[3-(2-Fluoro-4-methanesulfonyl-phenoxymethyl)-[1,2,4]triazol-1-yl]-piperidine-1-carboxylic acid tert-butyl ester;

4-[4-(2-Fluoro-4-tetrazol-1-yl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester;

4-[4-(4-Tetrazol-1-yl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester;

4-[4-(2-Fluoro-4-methanesulfonyl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester;

4-[5-(2-Fluoro-4-methanesulfonyl-phenoxymethyl)-tetrazol-2-yl]-Piperidine-1-carboxylic acid tert-butyl ester;

4-[3-(2-Fluoro-4-tetrazol-1-yl-phenoxymethyl)-pyrazol-1-yl]-piperidine-1-carboxylic acid tert-butyl ester;

4-[4-(2-Fluoro-4-tetrazol-1-yl-phenoxymethyl)-pyrazol-1-yl]-piperidine-1-carboxylic acid tert-butyl ester;

4-[4-(4-Tetrazol-1-yl-phenoxymethyl)-pyrazol-1-yl]-piperidine-1-carboxylic acid tert-butyl ester;

5-Ethyl-2-{4-[3-(2-fluoro-4-methanesulfonyl-phenoxymethyl)-[1,2,4]triazol-1-yl]-piperidin-1-yl}-pyrimidine;

5-Ethyl-2- {4-[4-(2-fluoro-4-methanesulfonyl-phenoxymethyl)-[1,2,3]triazol-2-yl]-pineridin-1-yl}-pyrimidine;

5-Butyl-2-{4-[4-(2-fluoro-4-methanesulfonyl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-pyrimidine;

5-Ethyl-2-{4-[4-(2-fluoro-4-tetrazol-1-yl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-pyrimidine;

5-Chloro-2-{4-[4-(2-fluoro-4-methanesulfonyl-phenoxymethyl)-[1,2,3]triazol-2-yl]-peperidin-1-yl}-pyrimidine;

2-{4-[4-(2-Fluoro-4-methanesulfonyl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-5-trifluoromethyl-pyrimidine;

2-{4-[4-(2-Fluoro-4-tetrazol-1-yl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-5-trifluoromethyl-pyrimidine;

5-Chloro-2-{4-[4-(2-fluoro-4-tetrazol-1-yl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-pyrimidine;

5-Chloro-2-{4-[5-(2-fluoro-4-methanesulfonyl-phenoxymethyl)-tetrazol-2-yl]-piperidin-1-yl}-pyrimidine;

2-(4-(4-((4-(1H-tetrazol-1-yl)phenoxy)methyl)-1H-pyrazol-1-yl)piperidin-1-yl)-5-ethylpyrimidine;

5-Ethyl-2-(4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-1H-pyrazol-1-yl)piperidin-1-yl)pyrimidine;

2-{4-[4-(2-Fluoro-4-tetrazol-1-yl-phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-5-methyl-pyrimidine;

4-[4-(4-Methanesulfonyl-phenoxymethyl)-[1,2,3]triazol-1-yl]-piperidine-1-carboxylic acid tert-butyl ester;

2-{4-[4-(6-Tetrazol-1-yl-pyridin-3-yloxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-5-trifluoromethyl-pyrimidine;

5-Chloro-2-{4-[4-(6-tetrazol-1-yl-pyridin-3-yloxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-pyrimidine;

1-[3-(1-Fluoro-1-methyl-ethyl)-[1,2,4]oxadiazol-5-yl]-4-[4-(2-fluoro-4-tetrazol-1-yl -phenoxymethyl)-[1,2,3]triazol-2-yl]-piperidine;

1-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)-4-[4-(2-fluoro-4-tetrazol-1-yl-phenoxymethyl) -[1,2,3]triazol-2-yl]-piperidine;

4-[4-(2-Fluoro-4-tetrazol-1-yl-phenoxymethyl)-[1,2,3]triazol-2-yl]-1-(3-isopropyl -[1,2,4]oxadiazol-5-yl)-piperidine;

5-{2[1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-4-yl]-2H-[1,2,3]triazol-4-ylmethoxy}-2-tetrazol-1-yl-pyridine;

5-(2-{1-[3-(1-Fluoro-1-methyl-ethyl)-[1,2,4]oxadiazol-5-yl]-piperidin-4-yl}-2H -[1,2,3]triazol-4-ylmethoxy)-2-tetrazol-1-yl-pyridine;

5-{2-[1-(3-Cyclopropyl-[1,2,4]oxadiazol-5-yl)piperidin-4-yl]-2H-[1,2,3]triazol-4-ylmethoxy}-2-tetrazol-1-yl-pyridine;

5-Fluoro-2-(4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine;

2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-fluoropyrimidine;

2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-ethylpyrimidine;

5-Chloro-2-((trans)-3-fluoro-4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine;

2-((trans)-3-Fluoro-4-(4((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-(trifluoromethyl)pyrimidine;

Isopropyl 4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

Isopropyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

Isopropyl 4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

5-Ethyl -2-((trans)-3-fluoro-4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine;

5-(4-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-ylsulfonyl)-2,4-dimethylthiazole;

5-((2-(1-(1H-Imidazol-4-ylsulfonyl)piperidin-4-yl)-2H-1,2,3-triazol-4-yl)methoxy)-2-(1H-tetrazol-1-yl)pyridine;

5-((2-(1-(Cyclopropylsulfonyl)piperidin-4-yl)-2H-1,2,3-triazol-4-yl)methoxy)-2-(1H-tetrazol-1-yl)pyridine;

5-((2-(1-(1-Methyl-1H-imidazo1-4-ylsulfonyl)piperidin-4-yl)-2H-1,2,3-triazol-4-yl)methoxy)-2-(1H-tetrazol-1-yl)pyridine;

4-(4-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)lmethyl)-2H-1,2,3-triazol-2-yl)piperidin-1-ylsulfonyl)-3,5-dimethylisoxazole;

5-((2-(1-(Cyclohexylsulfonyl)piperidin-4-yl)-2H-1,2,3-triazol-4-ly)methoxy)-2-(1H-tetrazol-1-yl)pyridine;

5-((2-(1-(lsopropylsulfonyl)piperidin-4-yl)-2H-1,2,3-triazol-4-yl)methoxy)-2-(1H-tetrazol-1-yl)pyridine ;

5-((2-(1-(Butylsulfonyl)piperidin-4-yl)-2H-1,2,3-triazol-4-yl)methoxy)-2-(1H-tetrazol-1-yl)pyridine;

5-((2-(1-(Benzylsulfonyl)piperidin-4-yl)-2H-1,2,3-triazol-4-yl)methoxy)-2-(1H-tetrazol-1-yl)pyridine;

2-(4-(4-((2-Methylpyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-ylsulfornyl)-5-(trifluoromethyl)pyrimidine;

(trans)-tert-Butyl 3-fluoro-4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

tert-Butyl4-(2-(4-((6-(1H-tetrazol-1-yl)pyridine-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-2-oxoethyl)piperidine-1-carboxylate;

-(4-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-2-piperidin-4-yl)ethanone hydrochloride;

Methyl 2-(2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidin-5-yl)acetate;

(S)-tert-Butyl 1-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-1-oxopropan-2-ylcarbamate;

(S)-tert-Butyl 1-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-1-oxopropan-2-ylcarbamate;

(S)-1-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-2-aminopropan-1-one hydrochloride;

(S)-tert-Butyl 4-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-4-oxo-1-(2,4,5-trifluorophenyl)butan-2-ylcarbamate;

(S)-1-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-3-amino-4-(2,4,5-trifluorophenyl)butan-1-one hydrochloride;

Ethyl 4-(2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidin-5-yl)butanoate;

(trans)-1-tert-Butyl 2-methyl 4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1,2-dicarboxylate;

Ethyl 4-(2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine-5-carboxylate;

2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidin-5-yl)(morpholino)methanone;

(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)(5-bromopyrimidin-2-yl)methanone;

tert-Butyl 4-(4-((6(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)octahydroquinoline-1(2H)-carboxylate;

2-(4-(4-((2-Methyl-6-(1H-1,2,4-triazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-(trifluoromethyl)pyrimidine;

5-Ethyl-2-(4-(4-((2-methyl-6-(1H-1,2,4-triazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine;

5-Ethyl-2-(4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)pvrimidine;

5-Ethyl-2-(4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-3-(trinuoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)pyrimidine;

5-Ethyl-2-(4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl)piperidin-1-yl)pyrimidine;

5-Chloro-2-(4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)-2-methylpiperidin-1-yl)pyrimidine;

2-(4-(4-((2-Fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)-2-methylpiperidin-1-yl)-5-(trifluoromethyl)pyrimidine;

exo-3-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1 ,2,3-triazol-2-yl)-8-(5-(trifluoromethyl)pyrimidin-2-yl)-8-azabicyclo[3. 2. 1]octane;

endo-tert-Butyl 3-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-8-azabicylo[3.2. 1]octane-8-carboxylate;

exo-tert-Butyl 3-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-8-azabicyclo[3.2.1]octane-8-carboxylate;

endo-3-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-8-(5-fluoropyrimidin-2-yl)-8-azabicyclo[3,2,1]octane;

exo-3-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-8-(5-fluoropyrimidin-2-yl)-8-azabicyclo[3.2.1]octane;

Allyl 4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

Allyl 4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2yl)piperidine-1-carboxylate;

2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxv)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl) -5-pentylpyrimidine;

Methyl 2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-6-methylpyrimidine-4-carboxylate:

2(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5(4-methoxyphenyl)pyrimidine;

Ethyl 2-(4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)thiazole-5-carboxylate;

2-(4-(4-((6(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-(trifluoromethyl)pyridine;

tert-Butyl 4-(4-((6-(1H-tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-3-methylpiperidine-1-carboxylate;

2-(4-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-3-methylpiperidin-1-yl)-5-(trifluoromethyl)pyrimidine;

2-(4-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-3-methylpiperidin-1-yl)-5-ethylpyrimidine;

2-(4-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-3-methylpiperidin-1-yl)-5-methylpyrimidine;

2-(4-(4-((6-(1H-Tetrazol-1-yl)pyridin-3-yloxy)methyl)-2H-1,2,3-triazol-2-yl)-3-methylpiperidin-1-yl)-5-chloropyrimidine;

2-(4-(4-((4-(1H-Tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-chloropyrimidine;

5-chloro-2-(4-(4-((2-Methyl-4(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine

2-((2-(1-(5-Chloropyrimidin-2-yl)piperidin-4-yl)-2H-1,2,3-triazol-4-yl)methoxy)-5-methyl-4(pyridin-3-yl)thiazole;

2-((2-(1-(5-Chloropyrimidin-2-yl)piperidin-4-yl)-2H-1,2,3-triazol-4-yl)methoxy)-5-methyl-4-(pyridin-4-yl)thiazole;

2-(4-(4-((4-((1H-1,2,3-Triazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-chloropyrimidine;

2-(4-(4-((4-(1H-1,2,4-Triazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-chloropyrimidine;

2-(4-(4-((4-(1H-Imidazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)-5-chloropyrimidine;

5-Chloro-2-(4-(4-((4-(Methylsulfonyl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine;

5-Chloro-2-{4-[4-(2-[1,3,4]oxadiazol-2-yl-phenoxymethyl)[1,2,3]triazol-2-yl]-piperidin-1-yl}-pyrimidine;

5-Chloro-2- {4-[4-(1-methyl-5-trifluoromethyl-1H-pyrazol-3-yloxymethyl)-[1,2,3]triazol-2-yl]-piperidin-1-yl}-pyrimidine;

5-Chloro-2- {4-[4-(6-chloro-pyridin-3-yloxymethyl)[1,2,3]triazol-2-yl]-piperidin-1-yl}-pyrimidine;

1-(4- {2-[1-(5-Trifluoromethyl-pyrimidin-2-yl)-piperidin-4-yl]-2H-[1,2,3]triazol-4-ylmethoxy}-phenyl)-pyrrolidin-2-one;

2-[4-(4-benzyloxymethyl-[1,2,3]triazol-2-yl)-piperidin-1-yl]-5-trifluoromethyl-pyrimidine;

Isobutyl 4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

Benzyl 4-(4-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

Isobutyl 4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

Benzyl 4-(4-((2-fluoro-4(methylsulfonyl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidine-1-carboxylate;

Ethyl 2-(4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)primidine-5-carboxylate;

Ethyl 2-(4-(4-(2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine-5-carboxylate;

5-Fluoro-2-(4-(4-((2-fluoro-4-(methylsulfonyl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)pyrimidine;

(4-(4-((2-Fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)(pyridin-2-yl)methanone;

(4-(4-((2-Fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)(6-hydrompyridin-2-yl)methanone;

(4-(4-((2-Fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)(3-hydroxypyridin-2-yl)methanone;

(4-(4-((2-Fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2-yl)piperidin-1-yl)(3-methylpyridin-2-yl)methanone;

(4-(4-((2-Fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-2H-1,2,3-triazol-2yl)piperidin-1-yl)(pyridin-3-yl)methanone, and

5-Ethyl-2-(4-(3-((2-fluoro-4-(1H-tetrazol-1-yl)phenoxy)methyl)-1H-pyrazol-1-yl)piperidin-1-yl)pyrimidine.

14. A method of raising intracellular levels of cyclic AMP (cAMP), said method comprising exposing a cell that expresses GPR119 to a compound of claim 1 .

15. The method of claim 14 , wherein said cell is a cell selected from the group consisting of a pancreatic cell, an islet cell, a beta cell, an intestinal endocrine cell, an L cell and a K cell.

16. A method of stimulating insulin production in a mammal, said method comprising administering an effective amount of a compound of claim 1 to said mammal.

17. A method of lowering blood glucose in a mammal, said method comprising administering an effective amount of a compound of claim 1 to said mammal.

18. A method of stimulating production of glucagon-like peptide 1 (GLP-1) or glucose dependent insulinotropic polypeptide (GIP) in a mammal, said method comprising administering an effective amount of a compound of claim 1 to said mammal.

19. A method of treating diabetes in a mammal, said method comprising administering an effective amount of a compound of claim 1 to said mammal.

20. A method of treating type 2 diabetes in a mammal, said method comprising administering an effective amount of a compound of claim 1 to said mammal.

21. A compound of claim 1 , which is of Formula III:

wherein,

X, Y and Z are each independently selected from the group consisting of N and C(R 3 );

the subscript q is 0, 1, or 2;

the subscript k is 1, 2 or 3;

R 1 is selected from the group consisting of H, C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 subsituted cycloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, —X 1 —C(O)R a , —X 1 —C(O)OR a , —X 1 —C(O)NR a R b , —S(O) 2 R a , a 4- to 7-membered heterocyclyl group, aryl and a 5- to 10-membered heteroaryl group, wherein each of said cycloalkyl group, heterocyclyl group, aryl group and heteroaryl group is optionally substituted with from 1 to 4 substituents independently selected from the group consisting of halo, C 1-10 alkyl, C 1-10 haloalkyl, C 3-7 cycloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl, —C(O)OR a , and —C(O)NR a R b , or optionally R a and R b are combined to form a 4-, 5- or 6-membered unsubstituted ring, and X 1 is selected from the group consisting of a bond, C 1-4 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, —C(O)—, and —C(O)(CH 2 ) 1-4 ; wherein R c and R d are independently H or C 1-10 alkyl;

each R 2 is independently selected from the group consisting of halo, C 1-5 alkyl, —C(O)R a , —C(O)OR a , —C(O)NR a R b , —OR a , —NR a R b , —NR a C(O)R b , —S(O)R a R b , —S(O) 2 R a and —S(O) 2 NR a R b , and wherein when the subscript q is 2, two R 2 groups can optionally cyclize to form a ring;

each R 3 is independently selected from the group consisting of H, halo, C 1-4 alkyl, and C 1-4 haloalkyl;

each R 6 is independently selected from the group consisting of halo, C 1-10 alkyl, C 1-10 substituted alkyl, C 3-7 cycloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, CN, NO 2 , —OR a , —NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —NR a C(O)R b , —NR a C(O)OR b , —NR a C(O)NR a R b , —SR a , —S(O)R a , S(O) 2 R a , —NR a S(O)R b , —NR a S(O) 2 R b , —S(O) 2 NR a R b , a 4- to 7-membered heterocyclyl group, aryl and a 5- to 10-membered heteroaryl group,

each R a and R b is independently selected from the group consisting of H, C 1-10 alkyl, C 1-10 haloalkyl, C 3-10 cycloalkyl, heterocyclyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl, 5- to 6-membered heteroaryl and arylC 1-4 alkyl; and

each R 7 and R 8 is independently selected from the group consisting of H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl;

or a pharmaceutically acceptable salt, stereoisomer, and/or ester thereof.

22. A compound of Formula IV:

wherein,

X, Y and Z are each independently selected from the group consisting of N and CH to form a 5-membered aromatic ring;

G is N or CR 3 ;

the subscript q is 0, 1 or 2;

the subscript k is 0, 1, 2 or 3;

R 1 is selected from the group consisting of —X 1 —C(O)R a , —X 1 —C(O)OR a , —X 1 —C(O)NR a R b , —S(O) 2 R a , a 4- to 7-membered heterocyclyl group, aryl and a 5- to 10-membered heteroaryl group, wherein each of said heterocyclyl group, aryl group and heteroaryl group is optionally substituted with from 1 to 4 substituents independently selected from the group consisting of halo, C 1-10 alkyl, C 1-10 haloalkyl, C 3-7 cycloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl, —C(O)OR a , and —C(O)NR a R b , or optionally R a and R b are combined to form a 4-, 5- or 6-membered unsubstituted ring, and X 1 is selected from the group consisting of a bond, —C(O)—, and —C(O)(CH 2 ) 1-4 —;

each R 2 is independently selected from the group consisting of halo, C 1-5 alkyl, —C(O)R a , —C(O)OR a , —C(O)NR a R b , —OR a , —NR a R b , —NR a C(O)R b , —S(O)R a R b , —S(O) 2 R a and —S(O) 2 NR a R b , and wherein when the subscript q is 2, two R 2 groups can optionally cyclize to form a ring;

R 3 is H, halo, C 1-4 alkyl, or C 1-4 haloalkyl;

each R 6 is independently selected from the group consisting of H, halo, C 1-10 alkyl, C 1-10 substituted alkyl, C 3-7 cycloalkyl, C 2-10 alkenyl, C 2-10 alkynyl, CN, NO 2 , —OR a , —NR a R b , —C(O)R a , —C(O)OR a , —C(O)NR a R b , —NR a C(O)R b , —NR a C(O)OR b , —NR a C(O)NR a R b , —SR a , —S(O)R a , S(O) 2 R a , —NR a S(O)R b , —NR a S(O) 2 R b , —S(O) 2 NR a R b , a 4- to 7-membered heterocyclyl group, aryl and a 5- to 10-membered heteroaryl group;

and each R a and R b is independently selected from the group consisting of H, C 1-10 alkyl, C 1-10 haloalkyl, C 3-10 cycloalkyl, heterocyclyl, C 2-10 alkenyl, C 2-10 oalkynyl, aryl, 5- to 6-membered heteroaryl and arylC 1-4 alkyl;

or a pharmaceutically acceptable salt, stereoisomer, and/or ester thereof.